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Chronic systemic inﬂammation is thought to be a major contributor to metabolic and neurodegenerative dis-
eases. Since inﬂammatory components are shared among different disorders, targeting inﬂammation is an
attractive option for mitigating disease. To test the signiﬁcance of inﬂammation in the lipid storage disorder
(LSD) Niemann-Pick C (NPC), we deleted the macrophage inﬂammatory gene Mip1a/Ccl3 from NPC diseased
mice. Deletion of Ccl3 had been reported to delay neuronal loss in Sandhoff LSD mice by inhibiting macro-
phage inﬁltration. For NPC mice, in contrast, deleting Ccl3 did not retard neurodegeneration and worsened
the clinical outcome. Depletion of visceral tissue macrophages also did not alter central nervous system
(CNS) pathology and instead increased liver injury, suggesting a limited macrophage inﬁltration response
into the CNS and a beneﬁcial role of macrophage activity in visceral tissue. Prevention of neuron loss or
liver injury, even at late stages in the disease, was achieved through speciﬁc rescue of NPC disease in neurons
or in liver epithelial cells, respectively. Local epithelial cell correction was also sufﬁcient to reduce the macro-
phage-associated pathology in lung tissue. These results demonstrate that elevated inﬂammation and macro-
phage activity does not necessarily contribute to neurodegeneration and tissue injury, and LSD defects in
immune cells may not preclude an appropriate inﬂammatory response. We conclude that inﬂammation remains
secondary to neuronal and epithelial cell dysfunction and does not irreversibly contribute to the pathogenic
cascade in NPC disease. Without further exploration of possible beneﬁcial roles of inﬂammatory mediators,
targeting inﬂammation may not be therapeutically effective at ameliorating disease severity.
INTRODUCTION
The continuous elevation of inﬂammatory cytokines, lyso-
somal defects in microglia and macrophages, and other
immune system irregularities have been proposed to play im-
portant roles in promoting tissue damage and neurodegenera-
tion in lipid storage disorders (LSDs) (1–6). If the
inﬂammatory process is harmful, therapeutically targeting
immune cells and inﬂammatory mediators may provide a
way to mitigate disease progression for these devastating
and as yet incurable diseases. Here, we explore the role of
inﬂammation in the severity and progression of the neurode-
generative lysosomal storage disease Niemann-Pick C (NPC).
NPC is a rare complex metabolic LSD that leads to progres-
sive deterioration of the nervous system and multiple organ
systems in the body (7). Although rare, NPC shares many mo-
lecular and pathological mechanisms with more common un-
related disorders. Patients with NPC have changes in brain
biomarkers that are associated with Alzheimer’s disease (8)
and suffer multiple neurological symptoms, such as dementia,
dystonia, seizures and psychiatric disorders. NPC also exhibits
a number of immune cell phenotypes. Macrophage foam cells
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well known for their role in atherosclerosis, where they form
plaques in the circulatory system (10). Mouse studies of
NPC have shown impaired natural killer T cell development
(11), as well as abnormal production of complement compo-
nents that are involved in the neuroinﬂammatory process of
many neurodegenerative diseases (12). Knowledge obtained
from studying NPC pathology will likely aid in understanding
pathological processes of other LSDs and of neurodegenera-
tive diseases with similar pathologies.
NPC disease is caused by genetic loss of NPC1 function
resulting in defective intracellular lipid ﬂux and accumulation
of lysosomal material that is potentially deleterious to cells.
NPC1 is a 13-pass endosomal/lysosomal membrane protein
that binds cholesterol, and more strongly oxysterols, in vitro
(13,14). While most cases of NPC disease are caused by
NPC1 gene mutations, NPC2 loss of function causes a
nearly identical disease. Unlike NPC1, NPC2 is a soluble
secreted sterol-binding protein that can be found in the
lumens of endosomes and lysosomes (15). It has been
hypothesized that both proteins shuttle cholesterol between
each other and endosomal/lysosomal membranes to facilitate
the exit of free cholesterol from the lysosome (16,17). A
defect in this process alters intracellular lipid homeostasis,
membrane properties and proper intracellular trafﬁcking of
organelles (18–20). The consequent accumulation of lyso-
somal material, e.g. sterols, gangliosides and sphingolipids,
is seen in virtually every cell in the body.
Despite a ubiquitous storage defect, only certain cell types,
such as neurons and hepatocytes, are particularly susceptible
to dysfunction and injury. Both NPC proteins are also essential
for proper macrophage and lymphocyte maturation and func-
tion (11,21–23), but whether defects in immune cells relate
to the pathogenesis of NPC disease is unclear. It is reasonable
to believe that aberrant or excessive inﬂammatory responses
elicited by NPC defects may contribute to disease pathology
and progression.
Although the genetic causes of NPC are well understood, how
best to mitigate disease pathology remains unknown. We set out
to determine to what extent immune cell activity inﬂuences NPC
disease progression. Investigations into NPC disease biology are
f a c i l i t a t e db yn a t u r a l l yo c c u rring mammalian models that recap-
itulate the human condition (24,25). In our effort to control in-
ﬂammation and correct NPC disease pathology, we pursued
various complementary approaches using the Npc1
2/2 mouse
model of the disease, also known as npc
nih (24).
To determine the contribution of macrophage and microglial-
mediated inﬂammation to the severity of NPC disease, we gen-
etically deleted the macrophage inﬂammatory protein 1alpha
gene, Mip1a/Ccl3. CCL3 protein is a known pro-inﬂammatory
cytokine that can mediate chemotaxis of monocytes and
promote cell degranulation (26). Ccl3 expression is elevated in
the central nervous system (CNS) and visceral tissue of many
LSDs, including Sandhoff disease, a prototypical autoimmune-
like LSD (27–32). The deletion of Ccl3 in a mouse model of
Sandhoff disease resulted in reduced monocyte-associated path-
ology in the brain, delayed neurodegeneration and prolonged
health (31). Sandhoff and NPC should share common patho-
logical mechanisms, since both disorders cause ganglioside
storage defects and immune cell impairment (33). If the NPC
pathogenic cascade behaves the same as in Sandhoff disease, de-
letion of Ccl3 should be beneﬁcial to Npc1
2/2 mice.
In a second approach, we determine whether the inﬂamma-
tory response and disease pathology is refractory to restoration
of NPC1 function after tissue damage has been established.
The ﬁndings obtained are critically important with respect to
determining the timing of treatments and in elucidating what
cell types are necessary to target to halt disease progression
and elicit recovery. Previously, it was postulated that the
failure of current treatments such as cyclodextrin (CYCLO)
to correct the pathology of tissues such as the lung was due
to the inability of CYCLO to reach lung macrophages
(27,34). This reasoning assumed that the activities of macro-
phages, driven by their own NPC storage defects, continuously
promote cell death and tissue injury in LSDs. To address these
issues, we used an established cell-speciﬁc transgene form of
gene therapy to genetically manipulate the production of
NPC1 with cell and tissue speciﬁcity in otherwise Npc1
2/2
mice. In the past, we exploited the cell-autonomous nature
of Npc1
2/2 defects in mice to show that neuron-speciﬁc
rescue, but not astrocyte-speciﬁc rescue, prevented or
delayed neurological disease signs (35). In this report, we
used features of the engineered mice that allowed control of
timing of NPC rescue. This temporal and cell-type-speciﬁc
rescue system allowed us to assess the importance of correct-
ing the NPC defect in Npc1
2/2 macrophages and microglia by
determining whether restoring NPC1 function only in neurons
and epithelial cells, even late in the disease, would be sufﬁ-
cient to halt cell injury and lessen the inﬂammatory response.
Together, our studies demonstrate that inﬂammatory media-
tors such as cytokines and macrophages have distinct disease
relevance even in LSDs with similar storage defects. Perturb-
ing part of the inﬂammatory pathway did not improve the
health of mice with NPC disease even though the same pro-
cedure was successful for mice with Sandhoff disease. We
propose that the role of inﬂammation in NPC disease is poten-
tially beneﬁcial and should be mainly viewed as a reaction to
local neuron and epithelial cell defects since disease pathology
can be halted or reversed by rescuing these cell types. Our
conclusions highlight the importance of determining the con-
tribution of each cell type to the clinical state of a particular
storage disorder in order to better justify whether or not to
pursue certain therapeutic avenues. The ﬁndings also have
implications for further classifying LSDs according to
whether macrophage activity and inﬂammatory mediators
cause or exacerbate cell injury.
RESULTS
Elevated regional Ccl3 expression in NPC-diseased mice
Elevated expression of genes encoding pro-inﬂammatory med-
iators has been previously observed in brains of Npc1
2/2 mice
at 21 days of age, and correlates well with increased glial-
mediated inﬂammation (12). Here, we show that at 50 days
of age, preceding a notable decline in mouse weight that indi-
cates deteriorating health, the expression of Ccl3 was ranked
using microarrays as one of the most elevated inﬂammatory
mediators in Npc1
2/2 mouse cerebella (Fig. 1A). Signiﬁcance
analysis of microarrays (SAM) (36), with the incorporation of
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Ccl3 expression as signiﬁcant (q-value ¼ 0) and among the
top 18 signiﬁcantly elevated genes listed, with afalse discovery
rate of 5.18% (Supplementary Material, Fig. S1). In addition to
Ccl3,thereiselevatedexpressionofcomplementpathwaycom-
ponents,other immunefactors,proteasesandlysosomal-related
protein genes at P50. Many of these genes are common
markers of inﬂammation and their expression is increased in
other LSDs and in neurodegenerative diseases, e.g. the LSDs
Sandhoff (37) and Gaucher (38), and Alzheimers (39).
Cytokine Ccl3 mRNA was elevated in Npc1
2/2 mice com-
pared with Npc1
+/2 mice in regions of the brain that have the
earliest and greatest signs of neurodegeneration and microglial
activity (Fig. 1B). The cerebellum and thalamus are the most
visibly affected brain structures and have the earliest onset of
neuronal loss (35). The brainstem shows a gradual increase in
neuroinﬂammation at later ages. The cortex does not have
microglia invasion as early or severe as in other brain areas,
even though considerable lipid accumulation is apparent in
neurons there (35). Ccl3 levels remain low in these regions
(Fig. 1B). In the viscera, elevated Ccl3 mRNA levels can be
readily detected in various tissues from Npc1
2/2 mice, includ-
ing the liver, an organ commonly affected by NPC disease.
To identify the major producers of Ccl3 in the body, we
examined isolated peritoneal cells, which are primarily macro-
phages and a few lymphocyte types (40). We also examined
tissue from spleen, the predominant storage center for macro-
phages as well as a minor hematopoietic organ in adult mice
(41). Levels of Ccl3 mRNA were elevated in peritoneal cells
and spleen from Npc1
2/2 mice compared with Npc1
+/2
mice (Fig. 1B). Based on these expression proﬁles, it is
likely that the CCL3 protein is mainly produced by microglia
and macrophages in the brain and visceral tissue of Npc1
2/2
mice, as expected (27,38,42).
Based on the observation that regions of increased Ccl3 ex-
pression correspond to areas of severe brain pathology, we
next asked whether Ccl3 and the inﬂammatory process
mediated by microglia and macrophage is important to NPC
pathology. Data from the Ccl3 gene deletion study using the
Hexb
2/2 mouse model of Sandhoff disease suggested that
CCL3 would likewise be a contributing factor in NPC
disease. Alternatively, CCL3 may have a neutral or beneﬁcial
role in the disease pathology.
Deletion of Ccl3 worsens the NPC disease outcome in mice
To determine whether CCL3 is required for disease progres-
sion in Npc1
2/2 mice, we crossed the same Ccl3
2/2 mouse
strain (43) previously used in the Sandhoff study to
Npc1
2/2 mice. As a standard for neuron rescue, we measured
weights of P60 male mice that were Npc1
2/2 but carried a
transgene that rescued Purkinje neurons speciﬁcally
(Fig. 2A). These mice were generated, as detailed in a prior
study (35), by mating an Npc1
+/2 mouse homozygous for a
Tet-inducible Npc1 transgene, tetO-Npc1-YFP (N), with a
Npc1
+/2 mouse homozygous for the cerebellar Purkinje
neuron-speciﬁc driver Pcp2-tTA (P). The resulting P; N;
Npc1
2/2 offspring produced NPC1-YFP protein in cerebellar
Purkinje neurons in an otherwise NPC1-deﬁcient animal. This
Purkinje neuron-speciﬁc correction of NPC disorder elicited
temporary but signiﬁcant health beneﬁts, such as weight
gain, relative to non-Purkinje rescued Npc1
2/2 mice. In con-
trast to Purkinje neuron-rescued mice, male Npc1
2/2 mice
carrying the Ccl3 deletion did not show any improvements
in weight (Fig. 2B). Ccl3
2/2; Npc1
2/2 mice instead were
more likely to exhibit lower weight proﬁles than Npc1
2/2
miceandhadtobeeuthanizedatagesearlierthanP70(Fig.2D).
A trend towards early death was also noticed for female
mice (data not shown), although differences in weight were
less obvious, possibly because young female mice do not
exhibit as much weight gain as young males. At around age
P60, the average weight difference between female Npc1
2/2
Figure 1. Ccl3 gene expression is elevated in the brain and visceral tissues of NPC mice. (A) We carried out gene expression proﬁle analyses of Npc1
2/2 mice
(NPC) compared with Npc1
+/2 mice (WT) cerebella at P50, an age before weight loss is detected in Npc1
2/2 mice (boxed inset, n ¼ 12). Ccl3 (black bar) was
among the most elevated mRNAs identiﬁed. Representative data from microarrays of cerebella from two age-matched Npc1
2/2 mice and three age-matched
Npc1
+/2 mice are shown. (B) Reverse transcription (RT)–polymerase chain reaction (PCR) analysis performed on Npc1
2/2 (Npc12) mice at age P60 revealed
region-speciﬁc elevation of Ccl3 mRNA in the brain compared with Npc1
+/2 (Npc1 +) mice. Highest expression was detected in the cerebellum (Cb), less in
brainstem (Bs) and lowest in the cortex (Cx). Elevated levels of Ccl3 mRNA were also detected in spleen (Sp), liver (Lv) and isolated peritoneal cells (Pt). (C)
Control RT–PCR showed the absence of a PCR product derived from Ccl3
2/2 (Ccl32) mouse liver samples. Actin was used to control for RT–PCR conditions
and representative data from RT–PCR on samples obtained from three mice are shown (B and C).
2948 Human Molecular Genetics, 2012, Vol. 21, No. 13mice (n ¼ 24) and Ccl3
2/2; Npc1
2/2 mice (n ¼ 13) was not
as striking (P ¼ 0.3237, t-test) as the difference between male
Npc1
2/2 mice (n ¼ 12) and Ccl3
2/2; Npc1
2/2 mice (n ¼ 18)
(Fig. 2B; P ¼ 0.0076, t-test). Two-way analysis of variance
performed on a cohort of nine male and ﬁve female pairs
further veriﬁed that between the ages of 45 and 60, weight




were not signiﬁcantly different (P ¼ 0.2028), but weight
curves of male mice were (P ¼ 0.0045).
The lower weight phenotype and earlier deaths of Ccl3
2/2;
Npc1
2/2 mice was unexpected. This worsening disease proﬁle
may be due to an inherent deleterious effect of Ccl3
2/2.T o
control for the effects of Ccl3
2/2 on non-diseased mice, we




+/2 P60 male mice. No gross weight differences were
seen at this age (Fig. 2C). Thus, Ccl3
2/2 affects weight
more notably in Npc1
2/2 mice than in Npc1
+/2 mice.
We also needed to consider genetic backgrounds, which may
greatly inﬂuence disease progression (44). The Ccl3
2/2;
Npc1
2/2 mice were on a mixed FVB and C57BL/6 (B6) back-
ground. B6 Npc1
2/2 mice life expectancy averages 28–35
days (45), while FVB Npc1
2/2 mice live for 72–83 days
(35). Despite this marked difference between the two back-
grounds, FVB/B6 Npc1
2/2 male mice readily survived past
P60 and their weights were comparable to FVB Npc1
2/2
mice (Fig. 2A, B, D). Thus, we attribute the lower weights
Figure 2. Ccl3 deletion worsens weight progression and macrophage-associated pathology in NPC mice. (A) The individual and average (color line) weight
values of diseased mice with rescued cerebellar Purkinje neurons (P; N; Npc1
2/2) were greater than Npc1
2/2 mice at age  P60. P; N; Npc1
2/2 and
Npc1
2/2 mice were in a FVB background. (B) In contrast, individual Ccl3
2/2; Npc1
2/2 FVB/B6 mice weights were, on average, lower than Npc1
2/2
FVB/B6 mice. A few Ccl3
2/2; Npc1
2/2 mice weights dipped past a predetermined cut-off weight for determining morbidity (dotted horizontal line above
gray zone). (C) The lack of difference in the average weight of Ccl3
2/2; Npc1
+/2 mice to Npc1
+/2 mice at age  P60 suggested a limited effect of the
Ccl3 gene deletion in non-diseased animals. (D) Representative weight curves of 13 Ccl3
2/2; Npc1
2/2 mice (red lines) and 11 Npc1
2/2 mice (black lines)
are shown. (A–D) Data from male mice are shown. (E) CD68 immunoﬂuorescence (red) depicts the differences in microglia/macrophage response in age-
matched cerebella at P65. Representative pathology from ﬁve mice is shown. Glial ﬁbrillary acidic protein (GFAP) immunoﬂuorescence (blue) depicts
Bergmann-glia and astrocytes in the cerebellum. Scale bar is 20 mm. (F) Percent areas of tissues that are CD68 positive in the cerebellum and liver were calcu-
lated for ﬁve Ccl3
2/2; Npc1
2/2 mice. (G) After injection of Dil-Lp (red) into the peritoneal cavity of Npc1
2/2 mice, which are Ccl3
+/+, the dye was taken up
by macrophages (green) in the liver. Scale bars: left panel 200 mm; right panel 20 mm. (H) Dil-Lp (red) was not taken up by microglia in the brain (green) and
remained in capillaries, identiﬁed by morphology. Scale bars: left panel 100 mm; right panel 10 mm. (I) Percent areas of tissues that were CD68 positive were
calculated for three Npc1
2/2 mice that received Clod-Lp peritoneal injections and three age-matched Npc1
2/2 mice that received control Lp injections. De-
pletion of CD68 occurred in the liver but not in the cerebellum.
Human Molecular Genetics, 2012, Vol. 21, No. 13 2949of Ccl3
2/2; Npc1
2/2 mice to the Ccl3 mutation, not to the
background genetic constitution.
Even if other factors were involved in worsening the disease
condition of Ccl3
2/2; Npc1
2/2 mice, none of the expected
weight gains and sustainability demonstrated with the Sandh-
off model was observed. In the Sandhoff study (31), Ccl3
2/2;
Hexb
2/2 mice had higher body weights and  30% longer
lifespans than Hexb
2/2 mice. Thus, in contrast to the inﬂuence
of CCL3 on Sandhoff disease, the endogenous production of
CCL3 may play a neutral or beneﬁcial rather than harmful
role in NPC disease.
The loss of CCL3 beneﬁted the Sandhoff Hexb
2/2 mouse
model, possibly because it lessened harmful microglia-
associated pathology in the CNS and inhibited macrophage in-
ﬁltration into the CNS. In order to determine whether CCL3
was also required to alter the macrophage and microglia-
associated pathology and inﬁltration in Npc1
2/2 mice, we
quantiﬁed the prevalence of CD68-positive cells in both vis-
ceral tissue and the CNS. CD68 is a marker of activated micro-
glia and macrophages.
Macrophages do not inﬁltrate the CNS
in NPC-diseased mice
In addition to not improving the weight proﬁle, deleting Ccl3 did
not alter the prevalence of CD68-positive cells in the CNS of
Npc1
2/2 mice (Fig. 2E and F). Analysis of liver tissues also
showed that, in Ccl3
2/2;N p c 1
2/2 mice, no signiﬁcant change
in CD68 staining was observed. In a few mice, however,
enlarged granuloma-like macrophage clusters were present,
which may have caused an increase in the average CD68 per-
centage calculated for the liver (Fig. 2D). The trend towards
increased macrophage-associated liver pathology in Ccl3
2/2;
Npc1
2/2 mice and lack of decrease in CD68-positive cells in
the CNS further suggests that endogenous CCL3 may play a
neutral or beneﬁcial role in modifying NPC disease pathology.
The main beneﬁt of deleting Ccl3 in Hexb
2/2 mice was
suggested to be inhibition of macrophage inﬁltration into the
CNS (31). In order to test whether peripheral macrophages
readily invade the CNS of Npc1
2/2 mice, we labeled or elimi-
nated peripheral macrophages with liposomes (Lp). Dil-label
and clodronate-toxin containing Lp (Dil-Lp and Clod-Lp, re-
spectively) have been used extensively in mice to selectively
deplete or label macrophages or microglia (41,46,47). When
Dil-Lp was injected into the peritoneal cavity of FVB
Npc1
2/2 mice at ages P52 or P70, Dil labeling of CD68-
positive macrophage cells was evident in the liver after 24
or 48 h (Fig. 2G). In these same mice, extremely few or no
CD68-positive cells were labeled with Dil in the brain.
Instead, Dil was sequestered in capillaries after 24 h
(Fig. 2H), suggesting that the Dil label is transportable to
the brain but that the blood-brain barrier restricted extravasa-
tion of Dil-Lp or Dil-Lp-carrying cells. Upon repeated periton-
eal injection of Clod-Lp from ages P50–P60, depletion of
CD68-positive cells from the liver, but not from the cerebel-
lum, was evident in Npc1
2/2 mice (Fig. 2I). These results
demonstrate that peripheral macrophages do not readily inﬁl-
trate and contribute to the CNS pathology in Npc1
2/2 mice.
The lack of noted macrophage inﬁltration into the CNS
of Npc1
2/2 mice is distinct from neuroinﬂammation in
Hexb
2/2 mice, where peripheral macrophages inﬁltrate the
brain and contribute to CNS pathology (31). This difference
may be the reason why deletion of CCL3 was not beneﬁcial
to Npc1
2/2 mice. To assess what additional inﬂuence CCL3
may have on inﬂammation and neurodegeneration, we used





Neuronal NPC1, not deletion of Ccl3, suppresses
neuroinﬂammation in NPC-diseased mice
Array analyses of Ccl3
2/2;N p c 1
2/2 mice compared with age-
matched and background-matched Npc1
2/2 cerebella showed
slight decreases in expression of cerebellar Purkinje neuron-
speciﬁc genes: Calb1/D28K, Pcp2, Stk17b/Drak2, Fgf7 and
Gpr63 (Fig. 3A). Decreased expression of these genes is likely
due to reduced numbers of surviving Purkinje neurons (48).
Stk17b, for example, is produced only in Purkinje neurons of
the cerebellum and serves as useful indicator of cell number
(Fig. 3C). The expression of Tyrosine hydroxylase (Th)c a n
also be used to assess the condition of Purkinje neurons in the
cerebellum in NPC disease since Th is ectopically expressed
in cerebellar Purkinje neurons as a consequence of the disease
(49). Th levels on average were higher in Ccl3
2/2;N p c 1
2/2
cerebella than in Npc1
2/2 mice (Fig. 3A and J). Based in part
on the reduction, though slight, of Purkinje neuron-speciﬁc
genes and mainly on the increase in Th, we conclude that the
loss of Ccl3 is deleterious to neurons in Npc1
2/2 mice.
Gene proﬁle array analysis revealed a general increase in ex-
pression of genes encoding lysosome-associated proteins,
secreted proteases and immune response factors (Fig. 1A)
in Ccl3
2/2;N p c 1
2/2 mice relative to Npc1
2/2 controls
(Fig. 3D and G). The elevation of these inﬂammatory factors
is thought to contribute to neurodegeneration. C1q, a main com-
ponent of the immune complement pathway, is of particular
interest since its production can promote microglial-mediated
removal of neuron synapses leading to neuronal death (50).
The expression of C1q is elevated early prior to signs of neuro-
degeneration in NPC disease (12) and here we ﬁnd that C1q
marks cells proximal to Purkinje neuron dendrites in a fashion
similar to CD68-positive microglia (Fig. 3F and I). Thus, micro-
glia and C1q-positive cells can be in physical contact with Pur-
kinje neuron dendritic spines to potentially mediate neuron
clearance in NPC disease. The increased expression and localiza-
tion of C1q has been conﬁrmed with RNA probe in situ hybrid-
ization (data not shown). The increase in C1q and other immune
components in Ccl3
2/2;N p c 1
2/2 mice further suggests that the
loss of Ccl3 is deleterious to neurons in Npc1
2/2 mice.
Despite increases in inﬂammatory factors, the pattern of Pur-
kinje neuron loss and invasion of CD68-positive microglia in
Ccl3
2/2;N p c 1
2/2 mice remains similar to that of Npc1
2/2
mice. As previously reported (35), CD68-positive microglia are
predominantly seen in areas of the cerebellum where Purkinje
neurons have degenerated and are absent from areas where
they still remain (Supplementary Material, Fig. S2). Thus, elim-
inating the inﬂammatory mediator CCL3 did not greatly alter the
neurodegenerative process or resulting microglial response. This
agrees with the conclusion that CCL3 may play a neutral or
beneﬁcial rather than a harmful role in modifying NPC disease.
2950 Human Molecular Genetics, 2012, Vol. 21, No. 13In a prior study, we reported that patterned Purkinje neuron
loss and microglial activity can be halted by neuron-speciﬁc
production of NPC1 in P; N; Npc1
2/2 mice (35). Here, we
assessed whether inﬂammatory factors in general can be
suppressed in NPC disease, without eliminating pro-
inﬂammatory components, such as CCL3. We performed
gene proﬁling array analysis on P; N; Npc1
2/2 mice, which
have early and constitutive production of a functional




2/2 FVB/B6 mice at various ages revealed a decrease or limited change in Purkinje neuron-speciﬁc genes and a general increase
in Th.( B) In contrast, microarray analysis between age-matched P; N; Npc1
2/2 and Npc1
2/2 FVB mice showed an increase in Purkinje neuron-speciﬁc genes
and consistently reduced Th RNA. P; N; Npc1
2/2 mice at age P100 were compared with Npc1
2/2 at P50, since Npc1
2/2 mice normally do not survive past age
P85. (C) As an example of Purkinje neuron speciﬁcity, confocal microscopy revealed STK17b protein (white) localized to the nuclear region of Purkinje neurons
immunostained with anti-D28K/CALB1 (red). In addition to increased Th, microarray analyses of Ccl3
2/2; Npc1
2/2 mice compared with controls revealed
increases in (E) lysosomal and protease-related genes and (G) complement and immune response genes. (E and H) The expression of these neuroinﬂammatory
components was substantially reduced in P; N; Npc1
2/2 mice. (F) Anti-CD68 highlighted microglia (white) encompassing Purkinje neuron dendrites (red). (I)
Similarly, C1q immunoﬂuorescence (white) dotted cell bodies could also be found in close proximity to Purkinje neuron dendrites (red). Confocal image stacks
were rendered in 3-D (F–I). Scale bars are 10 mm. (J) The trends for Th and Cd68 array data points are shown.
Human Molecular Genetics, 2012, Vol. 21, No. 13 2951NPC1-YFP protein in cerebellar Purkinje neurons (35). The
speciﬁc localization of YFP immunoﬂuorescence in Purkinje
neuron cell bodies, the reduction in ﬁlipin cholesterol stain
in Purkinje neurons, and the prevention of increased glial re-
activity only in the cerebellum helped conﬁrm that the
rescue speciﬁcally affected only those cells (35).
Compared with Ccl3 gene deletion, neuron-speciﬁc correc-
tion of NPC disease in P; N; Npc1
2/2 mice had a considerable
and opposite effect on neuroinﬂammation. Providing NPC1 to
Purkinje neurons in Npc1
2/2 mice maintained Purkinje
neuron-speciﬁc gene expression levels and suppressed
increases in Th (Fig. 3B and J, Supplementary Material,
Fig. S3). While Ccl3 gene deletion tended to increase the
levels of inﬂammation (Fig. 3D, G, J), all inﬂammatory
factors identiﬁed by array, including C1q, were suppressed
in the cerebella of P; N; Npc1
2/2 mice (Fig. 3E and H).
This demonstrates that much of the abnormal inﬂammatory
gene expression in the cerebella of Npc1
2/2 mice results
from neuronal defects that stimulate inﬂammatory cells,
rather than the loss of NPC1 from microglia.
The future of therapeutic approaches, genetic or otherwise,
for neurodegenerative disorders may depend on arresting the
progression of neuronal loss when a patient is already
exhibiting disease signs. For NPC disease, prior studies
demonstrated that neuronal NPC1 is required for neuron sur-
vival (35,51). However, these studies did not address
whether neuronal NPC1 is sufﬁcient to halt neuron loss late
in the disease after mice initially develop without NPC1 func-
tion. Methods of intrinsic neuron rescue will work only if the
early events in the disease do not set in motion an unstoppable
process of decay that contributes to non-autonomous neuronal
toxicity and elimination. Since neuron rescue and not deletion
of Ccl3 had such a dramatic effect on suppressing inﬂamma-
tion and preventing neuronal loss, we next focused on manipu-
lating the timing of neuron rescue to see whether NPC disease
could be arrested or reversed at late stages of the disease.
Arresting neurodegeneration late in NPC disease
progression
In order to test whether neuron rescue is possible late in the
disease, we regulated the production of NPC1-YFP in P; N;
Npc1
2/2 mice with Doxycycline (Dox). Dox binds to the
tTA protein produced by Pcp2-tTA and inhibits its ability to
induce the expression of a tetO- transgene (Fig. 4A). This
method has been previously been used to show
Figure 4. Neuronal survival remains intrinsically regulated despite the age of NPC-diseased mice. (A) Expression of the NPC1-YFP transgene in P; N; Npc1
2/2
was constitutively driven by Pcp2-tTA and could be inhibited by Dox applied at different ages (trials I–IV). (B) Example of cerebellar Purkinje neurons that
normally would produce NPC1-YFP in a P; N; Npc1
+/2 mouse showed no detectable NPC1-YFP immunoﬂuorescence enhanced by anti-green ﬂuorescent
protein (GFP) in the lobule III region of the cerebellum after Dox was given for over a week. Image is representative of results from four mice. (C) Depiction
of the difference in the number of surviving Purkinje neurons stained with D28K (red) per trial in cerebellar lobule III. (D) Representative quantitative analysis of
the number of remaining neurons in lobule III at a given age and per trial. Two mice were used per trial and trials (top graph) I, II, (bottom graph) III and IV were
performed in duplicate. The number of Purkinje neurons for wild-type (WT) mice (white bars are the same for each graph) was calculated by averaging together
Npc1
+/2 mice of approximate ages: P50, P60 and P70. For Npc1
2/2 mice of the following ages: P52, P65, P72 and P82 (gray bars are graphed for each age),
three or more mice were sampled for each age. Scale bars are 50 mm.
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the continuous expression of mutant ataxin-1 (52).
First, we tested whether suppression of the production of Pur-
kinje neuron NPC1-YFP in P; N; Npc1
2/2 mice with Dox
(Fig. 4B) can elicit neurodegeneration. Cerebellar lobule III
was chosen for analysis because of its consistent morphology
across mice of various ages and its early loss of Purkinje
neurons compared with more posterior lobules (53). In male
FVB Npc1
2/2 mice, Purkinje neuron loss starts to become ap-
parent in lobule III by age P50. By P65, Npc1
2/2 mice tend to
be devoid of Purkinje neurons in this cerebellar region. In sharp
contrast, P; N; Npc1
2/2 mice at age P88 have considerably
more neurons surviving in the lobule III region of the cerebel-
lum than Npc1
2/2 mice older than P72 (Fig. 4Ca n dD - t r i a lI ) .
When Dox is administered continuously to P; N; Npc1
2/2 mice
starting at P77, neuron loss commences. At P88, P; N; Npc1
2/2
mice that had been treated with Dox starting at P77 showed Pur-
kinje neuron loss that resembles the degree of Purkinje neuron
loss that occurs in Npc1
2/2 mice between P52 and P65
(Fig. 4D-trial II). Thus, removing NPC1 function from
neurons of adult P; N; Npc1
2/2 mice triggers degeneration of
neurons. These data from Npc1
2/2 mice support results
obtained from Npc1
+/+ mice with conditional knockout of
the Npc1 gene in mature neurons (51).
To demonstrate that providing NPC1 function to neurons
allows neuron survival even well along in the disease, we admi-
nistered Dox continuously to P; N; Npc1
2/2 mice from birth to
P52. Dox was removed at P52. By P52, inﬂammatory processes
have had ample time to intensify (Fig. 1A). When assessed at
age P67, these mice did not differ in the amount of Purkinje
neurons in lobule III compared with P52 Npc1
2/2 mice
(Fig. 4D-trial III). Thus, restoring NPC1-YFP production in
Purkinje neurons at P52 halted the neurodegenerative process
(Fig. 4C and D). If Dox was not removed at P52, then the
number of Purkinje neurons remaining in lobule III at P67 in
P; N; Npc1
2/2 mice was not signiﬁcantly different (P ¼
0.333 n ¼ 4 mice) than the number of Purkinje neurons typical-
ly remaining at P65 in Npc1
2/2 mice (Fig. 4D-trial IV). Thus,
neuronal NPC1 function is necessary for the survival of neurons
and sufﬁcient to arrest neurodegeneration.
Since neuron survival can be controlled even at late stages
of the disease without eliminating inﬂammatory mediators in
Npc1
2/2 mice, we hypothesized that other cell types vulner-
able to the disease could be rescued without targeting macro-
phages or immune cells in the body. NPC disease is a complex
disorder that affects multiple tissues in addition to the nervous
system. Notably, liver and pulmonary injuries are leading
causes of death of NPC patients (54–56). If macrophage-
associated pathology in visceral tissue operates in a fashion
similar to microglia-associated pathology in the CNS, then
correction of hepatic cells in the liver, for example, should
be sufﬁcient to suppress the inﬂammation even after tissue
pathology has become severe.
Reversing macrophage-associated NPC-diseased
tissue pathology
To test whether liver rescue is possible late in the disease,
we regulated the production of NPC1-YFP with the
ROSA26r-rtTA-M2 transgene (R)i nR; N; Npc1
2/2 mice
(35). rtTA is regulated in the opposite way from tTA; Dox
binding to rtTA induces expression of the tetO transgene
(Fig. 5A). It is also known that the ROSA26r-rtTA-M2 trans-
gene, in the presence of Dox, induces expression of a tetO
transgene in ﬁbroblasts and epithelial cells throughout the
body (57). Thus, in addition to being able to time NPC
rescue in visceral tissue of R; N; Npc1
2/2 mice, we were
also able to selectively test the importance of NPC1 function
in epithelial cells of various organs in the context of
NPC1-deﬁcient immune cells.
We found that the production of the NPC1-YFP protein was
inducible by Dox in non-macrophage cells both in vitro and in
vivo. In vitro, addition of Dox to culture media can induce
NPC1-YFP in primary ﬁbroblasts but not in peritoneal cells
isolated from R; N; Npc1
2/2 mice (Fig. 5B). In vivo, when
R; N; Npc1
2/2 mice were fed Dox, NPC1-YFP was produced
in the liver and detected by immunoﬂuorescence (Fig. 5B and
C). In these Dox-treated R; N; Npc1
2/2 mice, resident macro-
phages and invading monocytes or lymphocytes in the liver
did not have detectable NPC1-YFP protein. NPC1-YFP im-
munoﬂuorescence was also absent from the spleen and
restricted to a few cells in the thymus and bone marrow that
are not Thy1.2 positive (Fig. 5C and D). Thus, NPC1-YFP
was produced broadly in visceral tissue of R; N; Npc1
2/2
mice but was largely absent from monocytes, lymphocytes
and bone marrow cells.
Despite the lack of NPC1-YFP rescue in macrophages,
cholesterol accumulation in the liver of R; N; Npc1
2/2 mice
was modiﬁed after a week of NPC1-YFP induction
(Fig. 5E). Although some ﬁlipin stain persisted, it was now
in individual cells dispersed throughout the liver. These cells
lacked NPC1-YFP immunoﬂuorescence and were identiﬁed
as predominantly macrophages based on CD68 staining
(Fig. 5F). High-magniﬁcation imaging showed that macro-
phages in liver tissue of R; N; Npc1
2/2 mice had changed
from a foam cell appearance to a more ramiﬁed intermediate
state once liver epithelial cells or hepatocytes were genetically
rescued (Fig. 5G). With prolonged NPC1-YFP induction, the
majority of macrophages in the livers of R; N; Npc1
2/2
mice shared a resting state morphology equivalent to macro-
phages found in wild-type mice. Thus, macrophages in liver
remained responsive to their environment despite having a
continuous NPC1 defect.
Focal macrophage responses to changes in local environ-
ments within the same tissue can be seen upon brief (3–5
days) induction of NPC1-YFP in P65 or older R; N;
Npc1
2/2 mice. In the liver, foam cell macrophages clustered
in localized non-rescued liver areas, marked by lack of
green ﬂuorescent protein (GFP) immunoﬂuorescence and
intense ﬁlipin stain (Fig. 6A). Those areas may have been
sites of severe liver tissue injury, containing cells other than
hepatocytes that do not produce NPC1-YFP.
In lungs, a localized macrophage response was also seen.
Macrophages near simple squamous epithelial cells producing
NPC1-YFP had drastically thin morphology compared with
the large foam cell morphology of macrophages near lung epi-
thelia lacking NPC1-YFP (Fig. 6B). The macrophage morph-
ology change in lung was roughly quantiﬁed by the percent of
alveolar tissue area occupied by CD68 immunoﬂuorescence.
No change in morphology occurred in macrophages located
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alveoli, which happened to be bronchioles (Fig. 6C and D).
These results demonstrate, for the ﬁrst time, reversal of abnor-
mal macrophage behaviors in the lung of Npc1
2/2 mice.
Taken together, our rescue experiments in the brain, liver
and lung suggest that macrophage abnormalities in NPC are
driven by abnormal local tissue environments and not due to
intrinsic defects in NPC1 production. To more directly ascer-
tain the relative contribution of immune cells to NPC path-
ology, we pharmacologically depleted macrophages from the
viscera and compared liver injury with amount of liver
injury that resulted from hepatocyte epithelial cell rescue or
Ccl3 deletion.
Macrophage intervention is not required for reducing
tissue injury in NPC-diseased mice
Deletion of the macrophage inﬂammatory cytokine Ccl3 from
Npc1
2/2 mice (Fig. 7A) did not reduce the levels of the
hepatic enzyme alanine aminotransferase (ALT) in the blood
(Fig. 7D). Serum levels of ALT serve as a clinical marker of
hepatocyte injury, so we conclude that liver damage was not
reduced in Ccl3
2/2; Npc1
2/2 mice. A separate study also
observed that ALT levels were not reduced in a mouse knock-
out of the cytokine tumor necrosis factor (TNF)-alpha when
NPC liver disease was induced with NPC1-speciﬁc antisense
oligonucleotides (58). Despite little difference in ALT
levels, the authors noted that the loss of TNF-alpha delayed
macrophage-associated pathology in the liver. In our study,
ALT levels did correlate with the degree of
macrophage-associated liver pathology caused by deletion of
Ccl3 (Figs 2E and 7D). Given these reported phenotypes, it
remains uncertain whether macrophage activity in the liver
can be toxic to hepatocytes.
To explore the relevance of macrophages to liver injury, we
depleted liver macrophages from Npc1
2/2 mice using Clod-Lp
(Fig. 7B). Although repeated Clod-Lp injections caused some
toxicity, evident as a small increase in ALT levels in
non-NPC animals, if macrophage activity is harmful in NPC
disease the resulting smaller macrophage population should
have lessened liver injury in Npc1
2/2 mice. Instead, we saw
an average increase in ALT levels (Fig. 7E).
Serum ALT levels in Npc1
2/2 mice have been reduced only
when treatments targeted the storage accumulation in the liver
(27,54). These treatments, such as CYCLO, were not cell-
speciﬁc and thus have not revealed the cell type responsible
Figure 5. Macrophage-associated NPC liver pathology is corrected without immune cell rescue. (A) Expression of the NPC1-YFP transgene, driven by
Rosa-rtTA in R; N; Npc1
2/2 mice, can be induced with Dox at different ages (trials I–III). (B) Immunoblotting with anti-GFP demonstrated that, upon Dox
induction, NPC1-YFP protein was detected in liver tissue and cultured skin ﬁbroblast cells but not in isolated peritoneal cells. Representative data from
three animals are shown. (C) Immunoﬂuorescence with anti-GFP detected NPC1-YFP above tissue autoﬂuorescence in liver but not in spleen, and in
limited areas of the thymus. (D) Confocal imaging showed that NPC1-YFP immunoﬂuorescence did not colocalize with Thy1.2-positive cells in isolated
bone marrow cell clusters. These expression patterns (C and D) were observed for all mice used in this study. (E) Upon brief 1-week Dox induction of
NPC1-YFP, reduced cholesterol accumulation was seen in liver sections except in macrophages (yellow square and magniﬁed view). (F) Confocal 3-D rendering
demonstrated the absence of NPC1-YFP (green isosurface) in a representative CD68-positive cell (red) in the liver. (G) With prolonged Dox-induced
NPC1-YFP, the population of foamy CD68-positive cells reverted to a more ramiﬁed normal morphological appearance. Images of single CD68-positive
cells are representative of .50% of the cells in the tissue. Each trial, I–III, included a minimum of ﬁve mice. Scale bars are 50 mm.
2954 Human Molecular Genetics, 2012, Vol. 21, No. 13Figure 6. Macrophages respond locally to epithelial cell rescue. (A) Dox administered to P65 or older R; N; Npc1
2/2 mice produced a mosaic rescue effect in
liver tissue. Regions (inside semi-circle) that did not produce NPC1-YFP immunoﬂuorescence (GFP, green) remained cholesterol positive (Filipin, blue) and had
focal accumulation (arrow) of clustered macrophages (CD68, red). (B) In lung alveoli, foam cell CD68-positive macrophages (red) were seen proximal to simple
squamous epithelial cells (top panel). Macrophages near simple squamous epithelial cells producing NPC1-YFP (bottom panel, yellow arrow) were reduced in
size in comparison to the large foam macrophages surrounding non-NPC1-YFP-positive epithelial regions. (C) Apart from a few sparse squamous cells,
NPC1-YFP immunoﬂuorescence predominated in the epithelial linings (arrow) of bronchioles in R; N mice given Dox. (D) Quantiﬁcation of the percent
area that was CD68 positive in alveoli shows a signiﬁcant (P ¼ 0.0061, n ¼ 3 mice) decrease in CD68 in alveoli regions most proximal to bronchioles.
Scale bars are 50 mm.
Figure 7. Serum ALT levels are elevated in the absence of Ccl3 and macrophages but reduced when NPC1 is provided to hepatocytes. Depictions of treatment
target in liver of NPC mice. (A) Genetic deletion of cytokine Ccl3.( B) Depletion of peripheral macrophages. (C) NPC1 provision to hepatocytes. ALT blood
levels show (D) an average but not signiﬁcant increase in ALT levels from Ccl3
2/2; Npc1
2/2 compared with Npc1
2/2 FVB/B6 mice at age P58, (E) an average
but not signiﬁcant increase in ALT levels from Clod-Lp-treated Npc1
2/2 compared with control Lp-treated Npc1
2/2 FVB mice at age P56, and (F) an average
and statistically signiﬁcant decrease (P ¼ 0.0055) in ALT levels from Dox-treated R; N; Npc1
2/2 compared with Dox-treated Npc1
2/2 FVB mice at age P56.
Minimum of four mice was used for each ALT analysis.
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2/2 mice, we found
that genetically providing NPC1 function to epithelial cells in
the liver, but not macrophages (Fig. 7C), for a week was suf-
ﬁcient to normalize serum levels of ALT (Fig. 7F). Thus,
hepatic injury, like neuron injury, is primarily due to the
absence of NPC1 in the cell itself and not to an aberrant in-
ﬂammatory response or abundant immune cell activity.
DISCUSSION
Our experiments indicate that inﬂammation in the NPC mouse
model of LSD resembles a self-limiting inﬂammatory reac-
tion. Inﬂammation is described as self-limiting or acute
when it continues only until the threat to the cell is eliminated
and tissue homeostasis is restored (59). In Npc1
2/2 mice, we
demonstrate that correcting neuronal or epithelial cells is suf-
ﬁcient to suppress inﬂammation and reverse the
macrophage-associated pathology in tissues (Figs 3, 5 and
6). Furthermore, neuron loss and tissue injury could be
halted, even late in NPC disease, if neurons and epithelial
cells were treated before the cells were lost (Figs 4 and 7). Al-
though the NPC1 defect remains in macrophages and other
immune cells, we ﬁnd that this does not preclude resolution
of inﬂammation in NPC disease. The inﬂammatory response
remains a secondary response to tissue injury. This is encour-
aging news for modifying the disease progression of NPC
patients, even if diagnosis or treatment of the disease occurs
later in life.
Surprisingly, attempts to perturb the inﬂammatory response
by genetically deleting the macrophage inﬂammatory cytokine
Ccl3 or depleting activated macrophages from tissues in
Npc1
2/2 mice proved more deleterious than beneﬁcial as a
therapeutic approach (Figs 2, 3 and 7). These results provide
evidence that the inﬂammatory activity of microglia and
macrophages in NPC disease in response to cell defects and
injury may be a beneﬁcial adaptation to try and prevent exces-
sive tissue damage (Fig. 8). This view is supported by recent
in vitro data demonstrating that abundant Npc1
2/2 microglia
promote neuron survival of wild-type neurons in microglia-
neuron co-cultures (60). Whether similar events occur in
other LSDs has yet to be explored in sufﬁcient detail and in
appropriate models.
Deletion of Ccl3 allowed us to determine the relevance of
this cytokine to NPC disease progression and to experimental-
ly bridge NPC disease with the LSD Sandhoff disease. Our
results highlight an important distinction between NPC and
Sandhoff disease mouse models with regards to inﬂammation.
For the Npc1
2/2 mouse model of NPC disease, we now have
multiple lines of evidence to show that the degeneration of
neurons is governed by neuron-intrinsic defects. The elevation
of the inﬂammatory response itself does not drive elimination
of healthy neurons (Figs 3 and 4) and macrophage inﬁltration
into the CNS is not seen (Fig. 2). In the Hexb
2/2 mouse model
of Sandhoff disease, in contrast, macrophage invasion into the
CNS has been shown, and neuronal defects and inﬂammation
are proposed to converge to promote neurodegeneration (31).
To date, the pathogenic cascade of the Sandhoff disease model
has been the most widely proposed pathogenic cascade for
lysosomal storage diseases in general (1–3). The distinct
roles of inﬂammation in NPC and Sandhoff diseases,
however, argue for reevaluating the roles of neuroinﬂamma-
tion in other LSDs that have neurological deﬁcits.
Functional differences among LSDs may be concealed
behind overtly similar phenotypes, such as visible accumula-
tions of lysosome material or elevation of inﬂammatory com-
ponents. NPC and Sandhoff both accumulate
glycosphingolipids (33), which are potent immune modula-
tors, yet the same genetic treatment that beneﬁtted the Sandh-
off mouse model was deleterious to NPC mice (Figs 2 and 3).
NPC, Sandhoff and other LSDs also share multiple elevated
pro-inﬂammatory cytokines (37,38), yet the inﬂuence of
these cytokines may differ between disease states. Differences
in the roles of inﬂammation among LSDs may be better deter-
mined by properties speciﬁc to the pathways and cell types
involved. Thus, the role of inﬂammatory cells has to be care-
fully analyzed for an individual LSD and, if possible, the cell
types therapeutically relevant to treating the disease identiﬁed
in order to begin to categorize LSDs based on treatment poten-
tial.
Unlike lysosomal storage disorders that are caused by loss
of function of a secretable enzyme, NPC disease caused by
loss of transmembrane protein NPC1 function is cell autono-
mous. Providing NPC1 to one cell does not correct the
defect in another (35,53,61). Along with cell autonomy,
NPC disease also demonstrates tissue autonomy between
organ systems, so that an alteration, such as reduced inﬂamma-
tion, in one system or tissue area does not necessarily modify
the pathology in another. This is in contrast to the
non-cell-autonomous neurodegenerative mSOD1 mouse
model of amyotrophic lateral sclerosis, where immune modu-
lation in peripheral tissues such as the liver could potentially
result in a global neuroprotective intervention (62). For a
cell-autonomous neurodegenerative disease such as NPC,
global pathology is unlikely to be corrected by selective treat-
ment of speciﬁc tissues. Tissue autonomy in NPC disease is
demonstrated by the observation that peripheral monocytes
do not invade the brain in Npc1
2/2 mice (Fig. 2) and the
macrophage pathology in liver and lung can be locally
reduced depending on where in the tissue NPC1 is produced
(Figs 5 and 6). As a result, genetic or environmental risk
Figure 8. Proposed roadmap of NPC pathogenesis. Model for acute neurode-
generation and tissue injury in the lysosomal storage Niemann-Pick disease
type C. Line thickness represents degree of involvement.
2956 Human Molecular Genetics, 2012, Vol. 21, No. 13factors as well as therapeutic applications that affect a particu-
lar tissue system will elicit a modiﬁed clinical phenotype only
within the target tissue despite a similar NPC1 gene defect
throughout the body.
Future NPC research directions should focus on identifying
modiﬁers of the disease in order to better understand the vari-
ability in visceral tissue pathology seen in human patients
(63). Although late NPC disease pathology can be mitigated
(Figs 5–7), genetic variables and early developmental attri-
butes still appear to contribute to how the disease progresses.
The altered disease progression reﬂected by weight measure-
ments of Ccl3
2/2; Npc1
2/2 mice (Fig. 2) suggests that pre-
existing differences in the cytokine milieu can contribute to
disease severity, particularly in visceral tissue. Other factors,
genetic and environmental may also be involved (64).
Our results demonstrate that Npc1
2/2 macrophages and
immune cells respond appropriately to epithelial and neuronal
injury in NPC disease and that targeting cytokines produced
by macrophages or depleting macrophages in NPC disease
may inadvertently promote peripheral tissue or neuronal
injury. These characteristics of NPC disease pathology have
implications beyond NPC and the LSD research community
and may help treat disparate diseases, especially human im-
munodeﬁciency virus (HIV) and Ebola virus infection. The
processes of HIV and Ebola virus infection has been linked
to NPC disease through function of the NPC1 protein. Loss
of NPC1 alters transmission of HIV by affecting its packaging
and excretion from the infected cell (10). Loss of NPC1 limits
Ebola virus transmission by trapping Ebola in endocytic com-
partments of host cells, thereby preventing infection (65). In
both viral diseases, macrophages and lymphocytes are
believed to be the main reservoirs of the viruses and facilitate
virus transmission throughout the body. Based on the ﬁndings
reported here, inhibition of NPC1 function in macrophages
and immune cells could help moderate HIV and Ebola viral




Care and handling of mice was in accordance with institutional
guidelines. Mice homozygous for the Ccl3-targeted mutation
(JAX Mice Strain Name: B6.129P2-Ccl3
tm1Unc/J) were obtained
from The Jackson Laboratory. These C57BL/6 Ccl3
2/2 mice
were crossed to congenic FVB Npc1
2/2 mice (originally JAX
Mice Strain Name: BALB/cNctr-Npc1
m1N/J) previously gener-
ated in our laboratory (35). Offspring genotyped as Ccl3
+/2;
Npc1
+/2 was bred to produce experimental Ccl3
2/2;
Npc1





+/2 mice of mixed FVB/B6 background. The genotypes
of the Ccl3 and Npc1 loci were determined by PCR of
genomic DNA obtained from ear clips. Primers to detect the
mutations in the Ccl3 and Npc1 loci have been previously
described (31,35). Reverse transcription (RT)–polymerase chain
reaction (PCR) of liver total RNA was performed on half of
the Ccl3
2/2;N p c 1
2/2 mice generated in order to conﬁrm loss
of Ccl3 mRNA. A primer pair was used to generate a 433 bp
amplicon as follows: 5′-CCTCTGTCACCTGCTCAACATC-3′
and 5′- ATGTGGCTACTTGGCAGCAAAC-3′. Actin primer
pairs for control PCR, 5′-GCTCCGGCATGTGCAAAG-3′
and 5′-CCTCGGTGAGCAGCACAG-3′, generate a  283 bp
amplicon.
For humane reasons, mice were sacriﬁced under regulated
CO2 if lethargic and the body weight of a NPC-diseased
mouse dropped below 14 g for male mice or 12 g for female
mice older than P40. Weight measurements were made
every 2–7 days, or at ages reported. P; N; Npc1
2/2 and R;
N; Npc1
2/2 mice were generated in our laboratory as previ-
ously described (35).
Liposome treatment
Clodronate- and Dil-containing liposomes, as well as empty
vehicle liposomes, were purchased from Encapsula NanoS-
ciences. Approximately 200 ml of Dil-Lp solution was injected
into the peritoneal cavity of FVB P52 or P70 Npc1
2/2 mice.
Liver and brain tissue was dissected and analyzed 24–4 8h
later. Approximately 100 ml of Clod-Lp or control Lp solution
was injected into the peritoneal cavity of FVB Npc1
2/2 and
wild-type mice at days P49 and P53. Liver and brain analyses
were performed at P56.
Dox treatment
Mice were given Dox hyclate (Sigma) at a concentration of
2 mg/ml in their drinking water with 5% sucrose. The solution
was refreshed every 3 days and light-protected water bottles
were used. For R; N; Npc1
2/2 mice, induction of
NPC1-YFP was conﬁrmed by skin biopsy. The NPC1-YFP
ﬂuorescence produced by ﬁbroblast skin cells in the biopsy
can be detected by standard ﬂuorescent microscopy using a
×20 objective and GFP ﬁlter set.
Liver ALT
ALT plasma level analysis was performed in-house at the
Stanford University Veterinary Service Center. Ccl3
2/2;
Npc1
2/2 mice ALT was measured at age P58. Clod-Lp- and
Lp-treated mice ALT was measured at P56. For R; N;
Npc1
2/2 mice, ALT levels were measured at P56 after mice
were given Dox for 7 days.
Gene proﬁling
Cerebella from Ccl3
2/2;N p c 1
2/2 mice and sibling Npc1
2/2
mice, P; N; Npc1




+/2 mice were harvested and total
RNA was extracted with Trizol reagent (Invitrogen). A total
of 16 animals were used. Individual arrays were performed
on total RNA from each whole cerebellum isolated. Genomic
DNA was removed with Turbo DNA-free kit (Ambion) and
the RNA further puriﬁed with Acid Phenol:ChCl3 (Ambion)
and subsequent alcohol precipitation steps. A quality check of
RNA by Agilent Bioanalyzer QC, cDNA synthesis, hybridiza-
tion onto Affymetrix GeneChip
w Mouse Gene 1.0 ST Arrays
and scanning was performed at Stanford Protein and Nucleic
Acid Facility. Normalized intensity data were obtained using
the Affymetrix Expression Console software and RMA
Human Molecular Genetics, 2012, Vol. 21, No. 13 2957default settings. Intensity values and raw microarray data were
deposited in NCBI’s Gene Expression Omnibus (66)a n dc a nb e
viewed through GEO Series accession number GSE36119.
Known genes showing a 2-fold or greater increase in
Npc1
2/2 compared with Npc1
+/2 FVB mice at P50 were
ranked based on averages. SAM assessed signiﬁcance and the
functional groupings (Fig. 3) of the top  50 genes (Fig. 1)
were assigned using the Database for Annotation, Visualization
and Integrated Discovery (DAVID) (67).
Low-cycle RT–PCR analysis of Ccl3 RNA levels was per-
formed on total RNA isolated from various tissues and brain
regions of P60 Npc1
2/2 and Npc1
+/2 mice. The Ccl3 and
Actin primer pairs are noted above, under Transgenic Mice
section.
Immunoﬂuorescence, staining and quantiﬁcation
Primary antibodies used in this study: chicken anti-GFP
(Aves), chicken anti-Glial ﬁbrillary acidic protein (GFAP)
(Aves), chicken anti-Tyrosine Hydroxylase (Aves), rabbit
anti-Calbindin/D28K (Sigma), rat CD68 (Abdserotec), rabbit
anti-DRAK2 (Cell Signaling Technology), Thy1.2 (abcam),
rat C1q (abcam) and mouse anti-Actin (Millipore). Appropri-
ate Alexa and horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies were obtained from Invitrogen and
Jackson ImmunoResearch. Filipin (Sigma) was added with
secondary antibodies during staining.
For tissue immunoﬂuorescence microscopy, all tissues were
isolated and ﬁxed overnight in 4% paraformaldehyde phos-
phate buffer saline (PBS) solution at 48C, then sectioned
with a Vibratome into 50 mm slices. Brains were sectioned
sagitally. Bone marrow was extruded into ﬁxative. Tissue sec-
tions and bone marrow clumps were incubated with primary
antibody overnight at 48C in 2% bovine serum albumin
(BSA)/0.2% Triton X-100 PBS blocking solution. For tissue
treated with Dil-Lp, 2% BSA/0.1% Tween-20 PBS blocking
solution was used to preserve Dil localization. Blocking solu-
tions were used for washes at room temperature and secondary
incubation at 48C overnight followed by additional room tem-
perature washes. Tissue sections were mounted and sealed
onto slides. Bone marrow cells were pelleted and spread on
slides.
Epiﬂuorescent images were obtained using a Zeiss Axio-
plan2 ﬂuorescent microscope equipped with an AxioCam
HRc CCD camera. A 10% neutral density ﬁlter was used to
prevent photobleaching of ﬁlipin stain. Confocal images
were obtained with a Leica TCS SP2 laser-scanning micro-
scope. Images were processed and rendered using the Volocity
imaging software. Quantiﬁcation of the percent area of tissue
occupied by CD68 immunoﬂuorescence was measured using
the ImageJ software as previously described (35).
Cell isolation and immunoblot analysis
Peritoneal cells were isolated by syringe injecting 7 ml of cold
PBS into the peritoneal cavity of a euthanized mouse and as-
pirating back up 5 ml. Suspended peritoneal cells were centri-
fuged at 1000g for 5 min and PBS was replaced with the
complete growth medium and Dulbecco’s modiﬁed Eagle
medium (DMEM) (Gibco) with 10% fetal bovine serum
(FBS) (Thermo Scientiﬁc). Resuspended cells were allowed
to settle onto a plastic surface for 6 h. Remaining debris was
gently washed off. Dox was added to the remaining cells at
a concentration of 100 ng/ml for 48 h before immunoblotting
procedure. For RT–PCR analysis, freshly isolated peritoneal
cells were pelleted and placed in Trizol for RNA extraction.
Primary ﬁbroblast cells were cultured in complete medium,
DMEM with 10% FBS supplemented with normocin (Invivo-
gen), from tail biopsies of adult R; N; Npc1
2/2 mice. Finely
diced tail segments were seeded onto tissue culture plates
with low-level media to prevent ﬂoating of segments away
from ﬂoor of the plate. Partial media exchange was performed
daily until cell colonies beside large tissue pieces were seen.
Remaining tissue bits were removed and colony forming
cells were expanded. Dox was added to the remaining cells
at a concentration of 100 ng/ml for 48 h before immunoblot-
ting procedure.
For immunoblotting, equal numbers of cells or mass of liver
tissue were lysed in cold radioimmunoprecipitation assay
buffer supplemented with complete EDTA-free protease in-
hibitor cocktail mini tablets (Roche). Cells or tissue were
homogenized with motorized pestle. Insoluble material was
pelleted at 10 000g for 10 min. Supernatants were stored in
Laemmli protein sample buffer prior to electrophoresis in gra-
dient gels (Bio-Rad, Invitrogen). Primary antibodies were
incubated overnight at 48C in 2% BSA/0.2% Tween-20 PBS
solution. HRP-conjugated secondary antibodies were incu-
bated at room temperature for 30 min. The HRP chemilumin-
escence produced by adding SuperSignal West Pico
Chemiluminescent Substrate (ThermoScientiﬁc) was imaged
using a ChemiDoc XRS System (Bio-Rad).
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